| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer |
NCT02557295: An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA |
|
|
| Terminated | N/A | 248 | NA | | Celltrion | Rheumatoid Arthritis | 03/20 | 03/20 | | |
NCT02557308: An Observational Study to Evaluate Safety and Efficacy of Remsimaâ„¢ in Patients With Ankylosing Spondylitis |
|
|
| Recruiting | N/A | 1000 | RoW | | Celltrion | Ankylosing Spondylitis | 06/20 | 06/26 | | |
NCT05375942: This is a Retrospective Observational Study Looking at the Characteristics and Outcomes of Participants Taking Inflectra Using the CorEvitas Rheumatoid Arthritis Registry |
|
|
| Completed | N/A | 255 | US | Inflectra | Pfizer | Arthritis, Rheumatoid | 11/22 | 11/22 | | |
PEREM, NCT04990258: A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC |
|
|
| Active, not recruiting | N/A | 444 | Europe | Subcutaneous infliximab CT-P13 Remsima®SC | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, Celltrion | Inflammatory Bowel Diseases | 06/24 | 09/24 | | |
| Active, not recruiting | N/A | 22 | Europe | collection of clinical parameters and blood sample | Assistance Publique - Hôpitaux de Paris | Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis | 12/23 | 02/25 | | |
PRIME, NCT05722353: IBD Disease Course of Infliximab-naïve IBD Patients Treated With Subcutaneous Infliximab CT-P13 Remsima® |
|
|
| Recruiting | N/A | 120 | Europe | Biocollection | Assistance Publique - Hôpitaux de Paris | Inflammatory Bowel Diseases | 02/26 | 02/26 | | |
NCT05866614: A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps |
|
|
| Recruiting | N/A | 864 | Europe | Remsima IV, Remsima SC | Celltrion | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis | 03/27 | 03/27 | | |
